#continuousglucosemonitoring(cgm)

Senseonics Holdings, Inc. (NYSE American: SENS) and Rimidi are teaming up to create the Eversense Remote Patient Monitoring (RPM) Program, which will focus on improving diabetes care using new technology. Rimidi, known for its clinical management platform, wants to make managing chronic diseases, especially diabetes, easier for patients.

The partnership will combine Eversense glucose data with Rimidi's clinical management platform, which is used by health systems, health plans, and doctor's offices. This will work with Medicare's remote patient monitoring telehealth programs and fit into existing Electronic Health Record (EHR) systems. The goal is to improve care quality, streamline workflows, engage patients, and help with clinical decisions.

The Eversense CGM + RPM solution, with Rimidi's help, will securely send patient glucose data to popular EHR systems. This will give healthcare providers a better view of glucose trends, frequency of high or low events, and time spent in the target range. With this information, providers can work with patients to improve their lifestyle and therapy choices, leading to better diabetes management, lower costs, and better outcomes.

Tim Goodnow, PhD, President and CEO of Senseonics, explained that the Eversense RPM Program is part of their plan to combine long-term CGM technology with advanced analytics and personalized health services for a complete diabetes solution. This program aims to give providers the data they need to improve care between visits, where most diabetes management happens. The Eversense CGM+RPM solution, along with Rimidi's platform, aims to set Eversense apart from other CGM makers by offering a complete solution.